1. Home
  2. NCTY vs KRRO Comparison

NCTY vs KRRO Comparison

Compare NCTY & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The9 Limited American Depository Shares

NCTY

The9 Limited American Depository Shares

HOLD

Current Price

$5.23

Market Cap

93.8M

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$10.91

Market Cap

109.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCTY
KRRO
Founded
1999
2014
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.8M
109.7M
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
NCTY
KRRO
Price
$5.23
$10.91
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
20.0K
199.3K
Earning Date
03-27-2015
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$5.00
$5.20
52 Week High
$15.98
$55.89

Technical Indicators

Market Signals
Indicator
NCTY
KRRO
Relative Strength Index (RSI) 42.72 45.92
Support Level $5.02 $10.81
Resistance Level $7.22 $14.96
Average True Range (ATR) 0.56 0.86
MACD -0.03 -0.14
Stochastic Oscillator 13.74 9.98

Price Performance

Historical Comparison
NCTY
KRRO

About NCTY The9 Limited American Depository Shares

The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: